Publications

378 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

    The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...

    Report | 24-02-2022

  2. GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

    The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

    Report | 22-02-2022

  3. GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

    The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...

    Report | 10-02-2022

  4. Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

    The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

    Report | 25-01-2022

  5. Package advice tucatinib (Tukysa®)

    The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...

    Report | 17-01-2022

  6. Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia

    The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...

    Report | 17-01-2022

  7. GVS advice on volanesorsen (Waylivra)

    The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

    Report | 10-01-2022

  8. GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions

    The National Health Care Institute completed its assessment whether the further conditions of tezacaftor/ivacaftor (Symkevi®) and ...

    Report | 21-12-2021

  9. Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

    The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...

    Report | 15-12-2021

  10. GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis

    The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS. ...

    Report | 01-12-2021